Franz-Werner Haas, CureVac CEO (Thomas Kienzle/AFP via Getty Images)

Covid-19 roundup: Cure­Vac backs out of man­u­fac­tur­ing con­tracts as de­mand dwin­dles; De­spite PhII/III flop, biotech keeps look­ing for sil­ver lin­ing

Cure­Vac ter­mi­nat­ed con­tracts with two com­pa­nies who had signed on to help the Ger­man drug mak­er man­u­fac­ture its mR­NA Covid-19 vac­cine in Eu­rope, as po­ten­tial de­mand for its shot has dwin­dled.

Con­tracts with Wack­er for the man­u­fac­tur­ing of mR­NA drug sub­stance and Celonic for the man­u­fac­tur­ing and for­mu­la­tion of the mR­NA drug sub­stance for the drug, dubbed CVn­CoV, are no more. The com­pa­ny has held on to ex­ist­ing agree­ments with Rentschler Bio­phar­ma and No­var­tis for mR­NA pro­duc­tion, and said that those will not be af­fect­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.